What is the Exercise and Functionality: Outcomes Related to Treatment (EFFORT) study?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 15, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The EFFORT study is not mentioned in the provided evidence, and therefore, it is not possible to provide a definitive answer about the study based on the given information. However, based on the available evidence, it appears that exercise and physical activity are important for patients with various medical conditions, including heart failure, cancer, and coronary artery disease.

  • The evidence suggests that exercise training can improve functional capacity, reduce mortality and morbidity, and enhance quality of life in patients with heart failure 1.
  • In patients with cancer, exercise has been shown to reduce fatigue, improve functional outcomes, and enhance overall quality of life 1.
  • In patients with coronary artery disease, exercise testing and training can help assess functional capacity, predict prognosis, and improve outcomes 1.

It is essential to note that the evidence provided does not mention the EFFORT study, and therefore, any information about the study cannot be confirmed. In clinical practice, it is crucial to prioritize morbidity, mortality, and quality of life when making decisions about patient care, and to rely on the most recent and highest-quality evidence available.

From the Research

Overview of the EFFORT Study

  • The EFFORT study is mentioned in several different contexts, with varying focuses and objectives.
  • One of the EFFORT studies, referenced as 2, is titled "Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial" and investigates the efficacy of ertugliflozin in reducing functional mitral regurgitation in patients with heart failure.
  • Another study, referenced as 3, is called "Meeting nutritional targets of critically ill patients by combined enteral and parenteral nutrition: review and rationale for the EFFORTcombo trial" and explores the use of combined enteral and parenteral nutrition to achieve nutritional targets in critically ill patients.
  • A different study, referenced as 4, is titled "Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer" and examines the efficacy of FOLFIRI plus aflibercept as a second-line treatment for patients with unresectable or metastatic colorectal cancer.

Key Findings and Objectives

  • The EFFORT trial referenced in 2 found that ertugliflozin significantly improved left ventricular global longitudinal strain and left atrial remodeling, and reduced functional mitral regurgitation in patients with heart failure.
  • The study referenced in 3 aims to test the efficacy of an early combination of enteral and high-protein parenteral nutrition in reaching energy and protein goals in critically ill patients at high nutritional risk.
  • The EFFORT study mentioned in 4 seeks to evaluate the efficacy of FOLFIRI plus aflibercept as a second-line treatment for patients with unresectable or metastatic colorectal cancer who have progressed on FOLFOXIRI plus bevacizumab.

Study Designs and Populations

  • The EFFORT trial referenced in 2 is a multicenter, double-blind, randomized trial that enrolled 128 patients with heart failure and functional mitral regurgitation.
  • The study referenced in 3 plans to randomize nutritionally high-risk ICU patients to either high or low protein groups, with the high protein group receiving combined enteral and parenteral nutrition.
  • The EFFORT study mentioned in 4 is an open-label, multicenter, single-arm phase II study that will enroll patients with unresectable or metastatic colorectal cancer who have received FOLFOXIRI plus bevacizumab as a first-line therapy.

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is an alternative statin for a patient on Atorvastatin (Lipitor) 40?
What is the comparison between Atorvastatin (Lipitor) and Rosuvastatin (Crestor)?
Can Atorvastatin (generic name) be given to patients with elevated liver enzymes, and what dose would be appropriate?
What patient advice is recommended for a 34-year-old female in good health with hyperlipidemia, specifically elevated low-density lipoprotein (LDL) cholesterol, and hyperestrogenism?
What is the significance of elevated cholesterol levels, specifically Hypercholesterolemia (184 mg/dL), Hypertriglyceridemia (71 mg/dL), low High-Density Lipoprotein Cholesterol (HDL-C) (63 mg/dL), elevated Low-Density Lipoprotein Cholesterol (LDL-C) (105 mg/dL), high Cholesterol/HDL ratio (2.9), elevated Apolipoprotein B (92 mg/dL), and elevated Lipoprotein(a) (441 mg/dL)?
Should a patient with Urinary Tract Infection (UTI) symptoms be treated with minimal leukocyte esterase on urinalysis?
What does a negative straight leg raise (SLR) test in a sitting position, but a positive straight leg raise (SLR) test in a supine position, indicate?
What is the role of Hormone Replacement Therapy (HRT) in women more than 10 years post-menopause for the treatment of vasomotor symptoms?
What is the Endometriosis: Fertility, Ovarian, and Reproductive Treatment (EFFORT) study for endometriosis?
What is the cause of a 2-week history of aphonia (loss of voice) without improvement?
What is the cause of a 2-week history of aphonia (loss of voice) without improvement?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question